The North America AI In Evidence Access And Networks Market is expected to reach USD 1.11 billion by 2032, growing at a CAGR of 16.5% during 2026-2033.
The US market dominated the North America AI In Evidence Access And Networks Market by country in 2025, and is expected to continue to be a dominant market till 2033; thereby, achieving a market value of USD 865.01 million by 2032, growing at a CAGR of 15.8% during the forecast period.
The North America AI in Evidence Access and Networks Market has evolved from early AI-enabled information retrieval systems designed to improve evidence management across legal, healthcare, regulatory, and investigative environments. Initially focused on automating document classification and data indexing, the market has advanced significantly with the development of machine learning, natural language processing (NLP), predictive analytics, and network intelligence technologies.
Several transformative trends are shaping market growth. The increasing use of AI-powered evidence management platforms is improving healthcare research efficiency and accelerating clinical decision-making. Organizations are deploying predictive analytics and intelligent automation technologies to streamline evidence generation and improve treatment evaluation. Additionally, the expansion of interoperable healthcare networks is facilitating secure data sharing among pharmaceutical companies, healthcare providers, research organizations, and payers.
Component Outlook
Based on Component, the market is segmented into Data Platforms and Networks and Analytics and Technologies.
The Data Platforms and Networks market dominated the North America AI In Evidence Access And Networks Market by Component in 2025, and is expected to continue to be a dominant market till 2033; thereby, achieving a market value of USD 570.48 million by 2032, growing at a CAGR of 16% during the forecast period.
The Data Platforms and Networks segment accounted for the largest revenue share in 2025. Growth is supported by increasing implementation of integrated healthcare data ecosystems capable of aggregating, managing, and exchanging large volumes of clinical, operational, and real-world evidence data. Healthcare organizations, pharmaceutical companies, and research institutions increasingly utilize connected data platforms to improve interoperability, accelerate evidence discovery, and support evidence-based healthcare strategies.
Technology Outlook
Based on Technology, the market is segmented into Natural Language Processing (NLP), Machine Learning (ML) and Predictive Analytics, and Other Technology.
The Natural Language Processing (NLP) market dominated the North America AI In Evidence Access And Networks Market by Technology in 2025, and is expected to continue to be a dominant market till 2033; thereby, achieving a market value of USD 472.81 million by 2032, growing at a CAGR of 16.1% during the forecast period.
The Natural Language Processing (NLP) segment held the largest market share in 2025. Growth is driven by increasing utilization of NLP technologies to analyze clinical notes, physician documentation, medical literature, electronic health records, and research publications. NLP enables healthcare organizations to extract meaningful insights from large volumes of unstructured healthcare information and improve evidence accessibility.
The Machine Learning (ML) and Predictive Analytics segment recorded substantial growth due to rising implementation of predictive healthcare models, patient risk assessment tools, healthcare forecasting solutions, and precision medicine applications. Organizations increasingly leverage machine learning technologies to improve healthcare outcomes, optimize clinical trial performance, and support evidence-based treatment planning.
End User Outlook
Based on End User, the market is segmented into Pharmaceutical and Biotech Companies, Healthcare Providers and Payers, Contract Research Organizations (CROs), and Other End Users.
The Pharmaceutical and Biotech Companies segment accounted for the highest revenue share in 2025. These organizations increasingly utilize AI-powered evidence access platforms to support drug discovery, optimize clinical trials, improve patient recruitment, accelerate regulatory decision-making, and strengthen pharmacovigilance activities.
The Healthcare Providers and Payers segment experienced significant growth due to increasing adoption of AI-enabled evidence platforms for clinical decision support, population health management, healthcare resource optimization, and value-based care initiatives.
Data Source Outlook
Based on Data Source, the market is segmented into Electronic Health Records (EHR), Claims and Billing Data, Genomic and Omics Data, Patient Registries, and Other Data Sources.
The Electronic Health Records (EHR) segment generated the highest revenue share in 2025. Widespread adoption of digital health records and increasing healthcare data digitization have made EHRs a primary source for evidence generation, patient outcome analysis, and healthcare analytics.
The Claims and Billing Data segment recorded strong growth due to increasing demand for healthcare utilization analysis, reimbursement optimization, fraud detection, and healthcare cost management solutions.
Country Outlook
The US market dominated the North America AI In Evidence Access And Networks Market by country in 2025, and is expected to continue to be a dominant market till 2033; thereby, achieving a market value of USD 1.00 billion by 2033, growing at a CAGR of 15.8 % during the forecast period. The Canada market is expected to witness a CAGR of 19.3% during 2026-2033.
The United States dominates the North America AI in Evidence Access and Networks Market due to its strong healthcare infrastructure, advanced AI ecosystem, extensive adoption of electronic health records, and leadership in pharmaceutical and biotechnology innovation. Increasing investments in healthcare analytics, real-world evidence platforms, and precision medicine initiatives continue to drive market growth.
Canada is experiencing steady market expansion supported by growing investments in healthcare digitalization, evidence-based healthcare strategies, AI governance frameworks, and healthcare interoperability initiatives. Strong collaboration between government agencies, research institutions, and healthcare organizations is accelerating AI adoption across evidence access ecosystems.
List of Key Companies Profiled
By Component
The US market dominated the North America AI In Evidence Access And Networks Market by country in 2025, and is expected to continue to be a dominant market till 2033; thereby, achieving a market value of USD 865.01 million by 2032, growing at a CAGR of 15.8% during the forecast period.
The North America AI in Evidence Access and Networks Market has evolved from early AI-enabled information retrieval systems designed to improve evidence management across legal, healthcare, regulatory, and investigative environments. Initially focused on automating document classification and data indexing, the market has advanced significantly with the development of machine learning, natural language processing (NLP), predictive analytics, and network intelligence technologies.
Several transformative trends are shaping market growth. The increasing use of AI-powered evidence management platforms is improving healthcare research efficiency and accelerating clinical decision-making. Organizations are deploying predictive analytics and intelligent automation technologies to streamline evidence generation and improve treatment evaluation. Additionally, the expansion of interoperable healthcare networks is facilitating secure data sharing among pharmaceutical companies, healthcare providers, research organizations, and payers.
Component Outlook
Based on Component, the market is segmented into Data Platforms and Networks and Analytics and Technologies.
The Data Platforms and Networks market dominated the North America AI In Evidence Access And Networks Market by Component in 2025, and is expected to continue to be a dominant market till 2033; thereby, achieving a market value of USD 570.48 million by 2032, growing at a CAGR of 16% during the forecast period.
The Data Platforms and Networks segment accounted for the largest revenue share in 2025. Growth is supported by increasing implementation of integrated healthcare data ecosystems capable of aggregating, managing, and exchanging large volumes of clinical, operational, and real-world evidence data. Healthcare organizations, pharmaceutical companies, and research institutions increasingly utilize connected data platforms to improve interoperability, accelerate evidence discovery, and support evidence-based healthcare strategies.
Technology Outlook
Based on Technology, the market is segmented into Natural Language Processing (NLP), Machine Learning (ML) and Predictive Analytics, and Other Technology.
The Natural Language Processing (NLP) market dominated the North America AI In Evidence Access And Networks Market by Technology in 2025, and is expected to continue to be a dominant market till 2033; thereby, achieving a market value of USD 472.81 million by 2032, growing at a CAGR of 16.1% during the forecast period.
The Natural Language Processing (NLP) segment held the largest market share in 2025. Growth is driven by increasing utilization of NLP technologies to analyze clinical notes, physician documentation, medical literature, electronic health records, and research publications. NLP enables healthcare organizations to extract meaningful insights from large volumes of unstructured healthcare information and improve evidence accessibility.
The Machine Learning (ML) and Predictive Analytics segment recorded substantial growth due to rising implementation of predictive healthcare models, patient risk assessment tools, healthcare forecasting solutions, and precision medicine applications. Organizations increasingly leverage machine learning technologies to improve healthcare outcomes, optimize clinical trial performance, and support evidence-based treatment planning.
End User Outlook
Based on End User, the market is segmented into Pharmaceutical and Biotech Companies, Healthcare Providers and Payers, Contract Research Organizations (CROs), and Other End Users.
The Pharmaceutical and Biotech Companies segment accounted for the highest revenue share in 2025. These organizations increasingly utilize AI-powered evidence access platforms to support drug discovery, optimize clinical trials, improve patient recruitment, accelerate regulatory decision-making, and strengthen pharmacovigilance activities.
The Healthcare Providers and Payers segment experienced significant growth due to increasing adoption of AI-enabled evidence platforms for clinical decision support, population health management, healthcare resource optimization, and value-based care initiatives.
Data Source Outlook
Based on Data Source, the market is segmented into Electronic Health Records (EHR), Claims and Billing Data, Genomic and Omics Data, Patient Registries, and Other Data Sources.
The Electronic Health Records (EHR) segment generated the highest revenue share in 2025. Widespread adoption of digital health records and increasing healthcare data digitization have made EHRs a primary source for evidence generation, patient outcome analysis, and healthcare analytics.
The Claims and Billing Data segment recorded strong growth due to increasing demand for healthcare utilization analysis, reimbursement optimization, fraud detection, and healthcare cost management solutions.
Country Outlook
The US market dominated the North America AI In Evidence Access And Networks Market by country in 2025, and is expected to continue to be a dominant market till 2033; thereby, achieving a market value of USD 1.00 billion by 2033, growing at a CAGR of 15.8 % during the forecast period. The Canada market is expected to witness a CAGR of 19.3% during 2026-2033.
The United States dominates the North America AI in Evidence Access and Networks Market due to its strong healthcare infrastructure, advanced AI ecosystem, extensive adoption of electronic health records, and leadership in pharmaceutical and biotechnology innovation. Increasing investments in healthcare analytics, real-world evidence platforms, and precision medicine initiatives continue to drive market growth.
Canada is experiencing steady market expansion supported by growing investments in healthcare digitalization, evidence-based healthcare strategies, AI governance frameworks, and healthcare interoperability initiatives. Strong collaboration between government agencies, research institutions, and healthcare organizations is accelerating AI adoption across evidence access ecosystems.
List of Key Companies Profiled
- Oracle Corporation
- IQVIA Holdings Inc.
- Tempus AI, Inc.
- Flatiron Health, Inc.
- ConcertAI LLC
- Komodo Health, Inc.
- Datavant, Inc.
- Evidation Health, Inc.
- Ontada (McKesson Corporation)
- Aetion, Inc. (representative market participants)
By Component
- Data Platforms and Networks
- Analytics and Technologies
- Natural Language Processing (NLP)
- Machine Learning (ML) and Predictive Analytics
- Other Technology
- Pharmaceutical and Biotech Companies
- Healthcare Providers and Payers
- Contract Research Organizations (CROs)
- Other End Users
- Electronic Health Records (EHR)
- Claims and Billing Data
- Genomic and Omics Data
- Patient Registries
- Other Data Sources
- United States
- Canada
- Mexico
- Rest of North America
Table of Contents
Chapter 1. North America Market1.1 Market Overview
1.2 Key Factors Impacting Market
1.2.1 Market Drivers
1.2.2 Market Restraints
1.2.3 Market Opportunities
1.2.4 Market Challenges
1.2.5 Market Trends
1.2.6 State of Competition
1.2.7 Market Consolidation
1.2.8 Key Customer Criteria
1.3 Product Life Cycle
1.4 Segmentation By Component
1.4.1 Data Platforms and Networks
1.4.2 Analytics and Technology
1.5 Segmentation By Technology
1.5.1 Natural Language Processing (NLP)
1.5.2 Machine Learning (ML) and Predictive Analytics
1.5.3 Other Technology
1.6 Segmentation By End User
1.6.1 Pharmaceutical and Biotech Companies
1.6.2 Healthcare Providers and Payers
1.6.3 Contract Research Organizations (CROs)
1.6.4 Other End User
1.7 Segmentation By Data Source
1.7.1 Electronic Health Records (EHR)
1.7.2 Claims and Billing Data
1.7.3 Genomic and Omics Data
1.7.4 Patient Registries
1.7.5 Other Data Source
1.8 Segmentation By Country
1.8.1 US
1.8.1.1 Segmentation By Component
1.8.1.1.1 Data Platforms and Networks
1.8.1.1.2 Analytics and Technology
1.8.1.2 Segmentation By Technology
1.8.1.2.1 Natural Language Processing (NLP)
1.8.1.2.2 Machine Learning (ML) and Predictive Analytics
1.8.1.2.3 Other Technology
1.8.1.3 Segmentation By End User
1.8.1.3.1 Pharmaceutical and Biotech Companies
1.8.1.3.2 Healthcare Providers and Payers
1.8.1.3.3 Contract Research Organizations (CROs)
1.8.1.3.4 Other End User
1.8.1.4 Segmentation By Data Source
1.8.1.4.1 Electronic Health Records (EHR)
1.8.1.4.2 Claims and Billing Data
1.8.1.4.3 Genomic and Omics Data
1.8.1.4.4 Patient Registries
1.8.1.4.5 Other Data Source
1.8.2 Canada
1.8.2.1 Segmentation By Component
1.8.2.1.1 Data Platforms and Networks
1.8.2.1.2 Analytics and Technology
1.8.2.2 Segmentation By Technology
1.8.2.2.1 Natural Language Processing (NLP)
1.8.2.2.2 Machine Learning (ML) and Predictive Analytics
1.8.2.2.3 Other Technology
1.8.2.3 Segmentation By End User
1.8.2.3.1 Pharmaceutical and Biotech Companies
1.8.2.3.2 Healthcare Providers and Payers
1.8.2.3.3 Contract Research Organizations (CROs)
1.8.2.3.4 Other End User
1.8.2.4 Segmentation By Data Source
1.8.2.4.1 Electronic Health Records (EHR)
1.8.2.4.2 Claims and Billing Data
1.8.2.4.3 Genomic and Omics Data
1.8.2.4.4 Patient Registries
1.8.2.4.5 Other Data Source
1.8.3 Mexico
1.8.3.1 Segmentation By Component
1.8.3.1.1 Data Platforms and Networks
1.8.3.1.2 Analytics and Technology
1.8.3.2 Segmentation By Technology
1.8.3.2.1 Natural Language Processing (NLP)
1.8.3.2.2 Machine Learning (ML) and Predictive Analytics
1.8.3.2.3 Other Technology
1.8.3.3 Segmentation By End User
1.8.3.3.1 Pharmaceutical and Biotech Companies
1.8.3.3.2 Healthcare Providers and Payers
1.8.3.3.3 Contract Research Organizations (CROs)
1.8.3.3.4 Other End User
1.8.3.4 Segmentation By Data Source
1.8.3.4.1 Electronic Health Records (EHR)
1.8.3.4.2 Claims and Billing Data
1.8.3.4.3 Genomic and Omics Data
1.8.3.4.4 Patient Registries
1.8.3.4.5 Other Data Source
1.8.4 Rest of North America
1.8.4.1 Segmentation By Component
1.8.4.1.1 Data Platforms and Networks
1.8.4.1.2 Analytics and Technology
1.8.4.2 Segmentation By Technology
1.8.4.2.1 Natural Language Processing (NLP)
1.8.4.2.2 Machine Learning (ML) and Predictive Analytics
1.8.4.2.3 Other Technology
1.8.4.3 Segmentation By End User
1.8.4.3.1 Pharmaceutical and Biotech Companies
1.8.4.3.2 Healthcare Providers and Payers
1.8.4.3.3 Contract Research Organizations (CROs)
1.8.4.3.4 Other End User
1.8.4.4 Segmentation By Data Source
1.8.4.4.1 Electronic Health Records (EHR)
1.8.4.4.2 Claims and Billing Data
1.8.4.4.3 Genomic and Omics Data
1.8.4.4.4 Patient Registries
1.8.4.4.5 Other Data Source
Chapter 2. Company Snapshot
2.1 IQVIA Holdings, Inc.
2.1.1 Business Overview
2.1.2 Key Information
2.1.3 Company Focus
2.1.4 Strategic Insights
2.1.5 Strategy Deployed
2.1.6 Product & Service Portfolio
2.1.7 Capability Overview
2.1.8 Technology & Innovation Focus
2.1.9 Customers / End Users
2.1.10 Competitive Positioning
2.1.11 Key Differentiators
2.1.12 Portfolio Matrix
2.1.13 SWOT Analysis
2.1.14 Future Outlook
2.2 Optum, Inc. (UnitedHealth Group, Inc.)
2.2.1 Business Overview
2.2.2 Key Information
2.2.3 Company Focus
2.2.4 Strategic Insights
2.2.5 Strategy Deployed
2.2.6 Product & Service Portfolio
2.2.7 Capability Overview
2.2.8 Technology & Innovation Focus
2.2.9 Customers / End Users
2.2.10 Competitive Positioning
2.2.11 Key Differentiators
2.2.12 Portfolio Matrix
2.2.13 SWOT Analysis
2.2.14 Future Outlook
2.3 Flatiron Health, Inc.
2.3.1 Business Overview
2.3.2 Key Information
2.3.3 Company Focus
2.3.4 Strategic Insights
2.3.5 Strategy Deployed
2.3.6 Product & Service Portfolio
2.3.7 Capability Overview
2.3.8 Technology & Innovation Focus
2.3.9 Customers / End Users
2.3.10 Competitive Positioning
2.3.11 Key Differentiators
2.3.12 Portfolio Matrix
2.3.13 SWOT Analysis
2.3.14 Future Outlook
2.4 TriNetX, LLC
2.4.1 Business Overview
2.4.2 Key Information
2.4.3 Company Focus
2.4.4 Strategic Insights
2.4.5 Strategy Deployed
2.4.6 Product & Service Portfolio
2.4.7 Capability Overview
2.4.8 Technology & Innovation Focus
2.4.9 Customers / End Users
2.4.10 Competitive Positioning
2.4.11 Key Differentiators
2.4.12 Portfolio Matrix
2.4.13 SWOT Analysis
2.4.14 Future Outlook
2.5 Komodo Health, Inc.
2.5.1 Business Overview
2.5.2 Key Information
2.5.3 Company Focus
2.5.4 Strategic Insights
2.5.5 Strategy Deployed
2.5.6 Product & Service Portfolio
2.5.7 Capability Overview
2.5.8 Technology & Innovation Focus
2.5.9 Customers / End Users
2.5.10 Competitive Positioning
2.5.11 Key Differentiators
2.5.12 Portfolio Matrix
2.5.13 SWOT Analysis
2.5.14 Future Outlook
2.6 Oracle Corporation
2.6.1 Business Overview
2.6.2 Key Information
2.6.3 Company Focus
2.6.4 Strategic Insights
2.6.5 Strategy Deployed
2.6.6 Product & Service Portfolio
2.6.7 Capability Overview
2.6.8 Technology & Innovation Focus
2.6.9 Customers / End Users
2.6.10 Competitive Positioning
2.6.11 Key Differentiators
2.6.12 Portfolio Matrix
2.6.13 SWOT Analysis
2.6.14 Future Outlook
2.7 SAS Institute Inc.
2.7.1 Business Overview
2.7.2 Key Information
2.7.3 Company Focus
2.7.4 Strategic Insights
2.7.5 Strategy Deployed
2.7.6 Product & Service Portfolio
2.7.7 Capability Overview
2.7.8 Technology & Innovation Focus
2.7.9 Customers / End Users
2.7.10 Competitive Positioning
2.7.11 Key Differentiators
2.7.12 Portfolio Matrix
2.7.13 SWOT Analysis
2.7.14 Future Outlook
2.8 Aetion, Inc.
2.8.1 Business Overview
2.8.2 Key Information
2.8.3 Company Focus
2.8.4 Strategic Insights
2.8.5 Strategy Deployed
2.8.6 Product & Service Portfolio
2.8.7 Capability Overview
2.8.8 Technology & Innovation Focus
2.8.9 Customers / End Users
2.8.10 Competitive Positioning
2.8.11 Key Differentiators
2.8.12 Portfolio Matrix
2.8.13 SWOT Analysis
2.8.14 Future Outlook
2.9 ICON plc
2.9.1 Business Overview
2.9.2 Key Information
2.9.3 Company Focus
2.9.4 Strategic Insights
2.9.5 Strategy Deployed
2.9.6 Product & Service Portfolio
2.9.7 Capability Overview
2.9.8 Technology & Innovation Focus
2.9.9 Customers / End Users
2.9.10 Competitive Positioning
2.9.11 Key Differentiators
2.9.12 Portfolio Matrix
2.9.13 SWOT Analysis
2.9.14 Future Outlook
2.10 Syneos Health
2.10.1 Business Overview
2.10.2 Key Information
2.10.3 Company Focus
2.10.4 Strategic Insights
2.10.5 Strategy Deployed
2.10.6 Product & Service Portfolio
2.10.7 Capability Overview
2.10.8 Technology & Innovation Focus
2.10.9 Customers / End Users
2.10.10 Competitive Positioning
2.10.11 Key Differentiators
2.10.12 Portfolio Matrix
2.10.13 SWOT Analysis
2.10.14 Future Outlook
Companies Mentioned
- Oracle Corporation
- IQVIA Holdings Inc.
- Tempus AI, Inc.
- Flatiron Health, Inc.
- ConcertAI LLC
- Komodo Health, Inc.
- Datavant, Inc.
- Evidation Health, Inc.
- Ontada (McKesson Corporation)
- Aetion, Inc. (representative market participants)
